Patents by Inventor Philippe SAAS

Philippe SAAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cultured phagocyte supernatent compositions
    Patent number: 11793865
    Abstract: A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: October 24, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE BESANCON
    Inventors: Sylvain Perruche, Philippe Saas, Francis Bonnefoy
  • Use of HDL in the prophylaxis of graft-versus-host disease
    Publication number: 20220370551
    Abstract: This invention concerns a high-density lipoprotein (HDL) or HDL mimetic for use in the prevention and/or treatment of graft-versus-host disease (GvHD) or cytokine release syndrome in a subject.
    Type: Application
    Filed: September 10, 2020
    Publication date: November 24, 2022
    Inventors: Cécile CHAGUÉ, Etienne DAGUINDAU, Philippe SAAS
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20200237884
    Abstract: A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.
    Type: Application
    Filed: April 14, 2020
    Publication date: July 30, 2020
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON
    Inventors: Sylvain PERRUCHE, Philippe SAAS, Francis BONNEFOY
  • Disease therapy using a tolerogenic pharmaceutical preparation
    Patent number: 10653758
    Abstract: Provided herein is a method for treating or preventing a pathological immune response comprising administering a supernatant obtainable from co-culture of phagocytes with apoptotic cells.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: May 19, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE BESANC̨ON
    Inventors: Sylvain Perruche, Philippe Saas, Francis Bonnefoy
  • DISEASE THERAPY USING A TOLEROGENIC PHARMACEUTICAL PREPARATION
    Publication number: 20150343039
    Abstract: The present invention concerns pharmaceutical preparations to treat diseases characterized by a pathological immune response, methods of treatments using such preparations and processes for preparing said pharmaceutical preparations.
    Type: Application
    Filed: January 7, 2014
    Publication date: December 3, 2015
    Inventors: Sylvain PERRUCHE, Philippe SAAS, Francis BONNEFOY